One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator
Circulation: Arrhythmia and Electrophysiology · 2026
DOI: 10.1161/circep.125.014395 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2026. Verfasst von Michael S Lloyd und 25 weiteren Autor:innen. Beteiligte Einrichtung: Section of Cardiac Electrophysiology, Emory University, Atlanta, GA (M.S.L.). Hauptthemen laut MEDLINE: Cardiac Pacing, Artificial, Defibrillators, Implantable, Electric Countershock, Heart Rate. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
BACKGROUND: MODULAR antitachycardia pacing (ATP), a multicenter, international trial, assesses a modular cardiac rhythm management system: a subcutaneous implantable cardioverter defibrillator in wireless communication with a leadless pacemaker (LP) capable of pace-terminating ventricular tachycardia. METHODS: Enrolees had one or more clinical risk factors for ventricular tachycardia and did not require chronic pacing. Complications included prespecified major LP system- and procedure-related complications, and any complication related to the LP, subcutaneous implantable cardioverter defibrillator, implantation, or study protocol. Survival analysis was performed to identify complication-free rates, therapy delivery, and all-cause mortality. RESULTS: The 297 patients enrolled had an ejection fraction of 35±13%, 43% secondary prevention indications, and 59% with prior ventricular arrhythmias. Of 286 patients undergoing LP implantation (100% success), 251 patients completed 12-month follow-up. Mortality rate was 6%, with none related to the implant procedure. Median follow-up duration was 23.4 months (interquartile range, 17.9–28.1). The LP major complication-free rate was 97.2%, exceeding the performance goal. The overall LP+ subcutaneous implantable cardioverter defibrillator system-related complication-free rate was 88.5%. Appropriate tachyarrhythmia-therapy (ATP+shock) rates were 14.4%, and appropriate shock rates were 8.5%. Inappropriate total tachyarrhythmia therapy was 9.5% of which 8.5% were shocks. ATP was 67.3% successful in terminating ventricular arrhythmia episodes and accelerated ventricular arrhythmias in 10.1% of episodes. Overall therapy burden (ATP+shock) was 96/100 patient-years, of which 44/100 patient-years was for shock delivery. CONCLUSIONS: One-year outcomes of the first modular pacing-defibrillator system reveal low system and LP complication rates and good ATP efficacy rates, suggesting that the modular cardiac rhythm management is a viable alternative to single-chamber implantable cardioverter defibrillators using low-energy pacing capability without the need for transvenous leads. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov/ ; Unique identifier: NCT04798768.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Section of Cardiac Electrophysiology, Emory University, Atlanta, GA (M.S.L.).
- Cardiac Electrophysiology, Mount Sinai Fuster Heart Hospital, New York, NY (V.Y.R.).
- Clinical Cardiology Research, University Hospital Southampton, United Kingdom (P.R.).
- Cardiac Arrhythmia Group and HonorHealth Research Institute, Honor Health, Scottsdale, AZ (R.N.D.).
- Department of Cardiology, Liverpool Heart and Chest Hospital, United Kingdom (D.L.W.).
- Department of Cardiology, St Antonius Hospital, Nieuwegein, Utrecht, the Netherlands (L.V.A.B.).
ORCID-Profile: Michael S Lloyd, Vivek Y Reddy, Paul Roberts, Rahul N Doshi, David L Wright, Lucas V A Boersma, Paul A Friedman, Petr Neuzil, Carina Blomström-Lundqvist, Maria Grazia Bongiorni, Martin C Burke, Daniel Gras, Steven P Kutalek, Eloi Marijon, Jose María Tolosana, Anish K Amin, Laurence M Epstein, Johan D Aasbo, Thomas D Callahan, Amy J Brisben, Elizabeth Matznick, Tara N Bachman, Lluís Mont, Reinoud E Knops
Förderung
- Boston Scientific Corporation
Zitieren
APA
Lloyd, M. S., Reddy, V. Y., Roberts, P., Doshi, R. N., Wright, D. L., Boersma, L. V. A., Friedman, P. A., Neuzil, P., Blomström-Lundqvist, C., Bongiorni, M. G., Burke, M. C., Gras, D., Kutalek, S. P., Marijon, E., Tolosana, J. M., Amin, A. K., Epstein, L. M., Aasbo, J. D., Callahan, T. D., …, & Knops, R. E. (2026). One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator. Circulation: Arrhythmia and Electrophysiology. https://doi.org/10.1161/circep.125.014395
Vancouver
Lloyd MS, Reddy VY, Roberts P, Doshi RN, Wright DL, Boersma LVA, et al. One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator. Circulation: Arrhythmia and Electrophysiology. 2026. doi:10.1161/circep.125.014395
BibTeX
@article{Lloyd2026,
author = {Lloyd, Michael S and Reddy, Vivek Y and Roberts, Paul and Doshi, Rahul N and Wright, David L and Boersma, Lucas V A and Friedman, Paul A and Neuzil, Petr and Blomström-Lundqvist, Carina and Bongiorni, Maria Grazia and Burke, Martin C and Gras, Daniel and Kutalek, Steven P and Marijon, Eloi and Tolosana, Jose María and Amin, Anish K and Epstein, Laurence M and Aasbo, Johan D and Callahan, Thomas D and Brisben, Amy J and West, Julie and Matznick, Elizabeth and Speakman, Benjamin and Bachman, Tara N and Mont, Lluís and Knops, Reinoud E},
title = {One-Year Outcomes of the MODULAR ATP Trial: A Novel Leadless Pacemaker in Wireless Communication With a Subcutaneous Implantable Cardioverter Defibrillator},
journal = {Circulation: Arrhythmia and Electrophysiology},
year = {2026},
doi = {10.1161/circep.125.014395}
}
EUVIMED